Today at Coriell, one team is responsible for a sample’s care from beginning to end—the Biobanking Logistics team. This department manages a complex and wide range of tasks and responsibilities to ensure the samples in our care are received and stored properly, and shipped with care to researchers.
read moreFor those affected by a rare disease, there is an accessible way to contribute to the research effort. The Human Genetic Cell Repository (HGCR), sponsored by the National Institute of General Medical Sciences (NIGMS) and hosted at the Coriell Institute, contains many thousands of cell line and DNA samples derived from tissue donations from affected people, allowing researchers to study these diseases and develop new therapies. The collection of samples representing rare diseases is always growing!
read moreDozens of induced pluripotent stem cell (iPSC) lines were added to the collections in Coriell's care last year. See a full list of new lines here.
read moreThe Epigenetic Therapies SPORE offers $50,000 grants through its Career Enhancement and Developmental Research programs to scientists interested in the research of epigenetic therapies in cancer. For more information, including eligibility and award details, kindly review the Request for Applications.
read moreThis past year was another of growth and impact for the Coriell Institute for Medical Research, as detailed here in our 2022 Annual Report. Key milestones and achievements were accomplished in each pillar of our mission.
read moreHow might your aging research benefit from or contribute to the National Institute on Aging (NIA) Aging Cell Repository? A recent webinar hosted by the NIA's Research Centers Collaborative Network explored the background of the collection held at Coriell, an introduction to induced pluripotent stem cells, and and the important role the Aging Cell Repository plays in aging research today.
read moreFirst established at Coriell in 1972, this collection of cells and DNA is one of the very first at Coriell and is an extension of our founder Dr. Lewis L. Coriell’s mission: To provide scientists around the world with standardized biomaterials of the highest quality to support research.
read moreWhile the United States continues to battle an addiction and overdose epidemic that has caused great harm across the nation, prescription opioid painkillers remain a common tool in managing chronic pain. In an open access article published this month in Pharmaceutics, researchers working with the Camden Opioid Research Initiative (CORI) have demonstrated that the majority of study patients are open to pharmacogenetic testing as part of their medication management. Pharmacogenetics is the study of genetic variation that impacts each individual’s response to medications.
read moreThis collection, housed at the Coriell Institute for Medical Research since its creation, contains cell lines, DNA, and extensive de-identified clinical data from thousands of patients diagnosed with a wide range of neurological disorders, including some of the most pressing diseases of our time—stroke, parkinsonism, and several others.
read moreA Q&A with Jacqueline Smith at the Allen Institute for Cell Science
read more